The reduction in price target by Benchmark could have a mixed impact on Humacyte's stock price. While the Buy rating reaffirms a positive outlook, the lowered price target may signal a tempered expectation for the stock's growth potential. Investors may perceive the price target cut as a negative signal, potentially leading to short-term price volatility. However, the continued Buy rating suggests that the overall sentiment remains positive, which could mitigate any negative reaction.